<DOC>
	<DOCNO>NCT00376259</DOCNO>
	<brief_summary>This study conduct compare safety effectiveness investigational medication LdT ( telbivudine ) use combination adefovir dipivoxil ( drug currently approve Food Drug Administration [ FDA ] treatment hepatitis B virus [ HBV ] ) versus adefovir dipivoxil use alone . The result patient take combination therapy compare result patient take adefovir alone .</brief_summary>
	<brief_title>Study Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Documented compensate chronic hepatitis B define clinical history compatible chronic hepatitis B . Previous current lamivudine treatment HBV DNA &gt; 6 log10 copies/mL Evidence viral breakthrough Other protocoldefined inclusion criterion may apply . Patient pregnant breastfeeding . Patient coinfected hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) , HIV . Patient receive antiHBV treatment HBV infection lamivudine 12 month Screening study . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>lamivudine resistance</keyword>
	<keyword>Hepatitis B virus</keyword>
</DOC>